|Uncovering the mechanisms of disease progression in genetic subsets of lung cancer
|Thales Y. Papagiannakopoulos, PhD
|Department of Pathology, New York University Grossman School of Medicine/
Laura and Isaac Perlmutter NYU Cancer Center, New York University
Grossman School of Medicine
|本橋 ほづみ（所属 遺伝子発現制御分野・内線8550）
KRAS mutant lung adenocarcinoma is the major form of lung cancer that remains a major challenge for clinical oncology because patients are refractory to standard-of-care. KRAS mutant tumors display a high degree of genetic heterogeneity and emerging clinical data suggest that specific KRAS co-mutations are associated with poor prognosis and failure of cancer therapies. Our group uses genetically engineered mouse models and patient samples to dissect how genetic subsets of KRAS mutant lung cancer promote tumorigenesis by rewiring cancer cell metabolism, promoting immune evasion and therefore contributing to tumor progression and therapy resistance. We have identified novel therapeutic approaches to both suppress tumor metabolism and reverse the immunosuppressive microenvironment of genetic subsets of KRAS-driven lung cancer.
Furthermore, our group is investigating how cancer as a systemic disease can lead to dysfunction of multiple organ systems, which is observed in many lung cancer patients. We are dissecting the interplay of tumor mutations, nutrition and changes in systemic physiology during tumorigenesis. Our preliminary studies highlight that genetic subtypes of KRAS mutant lung cancer can interact with common diets to disrupt systemic physiology. We aim to identify and therapeutically target the underlying mechanisms in order to restore homeostatic control of physiological functions.